Novo Nordisk inks $2.1B oral obesity drug deal

Ella Jeffries / beckershospitalreview - Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is e…

AI Summary: Novo Nordisk has struck a multibillion‑dollar deal with Vivtex to develop next‑generation oral biologic therapies for obesity and related metabolic diseases. The partnership funnels major R&D resources into oral delivery technology, signaling the company’s bet that pills — not injections — will be the next commercial battleground in weight‑loss medicine.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Novo Nordisk GLP‑1 Trials Fail to Check Alzheimer’s Progression / 6 months

Novo Nordisk Seeks FDA Nod for Higher‐Dose Wegovy / 6 months

Lilly’s Zepbound bests Novo’s CagriSema in head‑to‑head obesity trial / 3 months

JP Morgan Healthcare Conference 2026: Pharma, AI, and Innovation Highlights / 4 months

Novo Nordisk oral GLP‑1 pill clears FDA for obesity treatment / 5 months

Novo launches high‑dose Wegovy in US at $399 for self‑pay patients / 7 wks

Neurocrine buys Soleno Therapeutics for $2.9B to gain Prader‑Willi drug / 7 wks